US Stock MarketDetailed Quotes
ATRA Atara Biotherapeutics
- 7.630
- -0.500-6.15%
Close Oct 1 16:00 ET
- 7.629
- -0.001-0.01%
Post 17:01 ET
43.29MMarket Cap-195P/E (TTM)
8.260High7.460Low122.32KVolume8.120Open8.130Pre Close936.93KTurnover2.60%Turnover RatioLossP/E (Static)5.67MShares45.75052wk High-0.39P/B35.83MFloat Cap4.96552wk Low--Dividend TTM4.70MShs Float1638.998Historical High--Div YieldTTM9.84%Amplitude4.965Historical Low7.659Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Atara Biotherapeutics Stock Forum
Should see increased acitivity soon as all these large investors have interest in this comp...
good buy
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
Atara Biotherapeutics (Nasdaq: ATRA) has announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering, priced at $8.25 per share, represents a 15% premium to Atara's 7-day volume-weighted average price. Participants include existing top institutional investors and a new strategic investor from a large public biotechnology company. The proceeds wi...
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3...
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA
No comment yet